Literature DB >> 25911748

Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

M Christian Tjiam1, James P A Taylor2, Mazmah A Morshidi2, Lucy Sariputra2, Sally Burrows3, Jeffrey N Martin4, Steven G Deeks5, Dino B A Tan6, Silvia Lee7, Sonia Fernandez2, Martyn A French8.   

Abstract

Identifying the mechanisms of natural control of HIV-1 infection could lead to novel approaches to prevent or cure HIV infection. Several studies have associated natural control of HIV-1 infection with IgG Abs against HIV-1 Gag proteins (e.g., p24) and/or production of IgG2 Abs against HIV-1 proteins. These Abs likely exert their effect by activating antiviral effector cell responses rather than virus neutralization. We hypothesized that an opsonophagocytic IgG Ab response against HIV-1 p24 that activates plasmacytoid dendritic cells (pDCs) through FcγRIIa would be associated with control of HIV and that this would be enhanced by Ab isotype diversification. Using the Gen2.2 pDC cell line, we demonstrated that pDC-reactive opsonophagocytic IgG Ab responses against HIV-1 p24 were higher in HIV controllers (HIV RNA < 2000 copies/ml) than noncontrollers (HIV RNA > 10,000 copies/ml), particularly in controllers with low but detectable viremia (HIV RNA 75-2000 copies/ml). Opsonophagocytic Ab responses correlated with plasma levels of IgG1 and IgG2 anti-HIV-1 p24 and, notably, correlated inversely with plasma HIV RNA levels in viremic HIV patients. Phagocytosis of these Abs was mediated via FcγRIIa. Isotype diversification (toward IgG2) was greatest in HIV controllers, and depletion of IgG2 from Ig preparations indicated that IgG2 Abs to HIV-1 p24 do not enhance phagocytosis, suggesting that they enhance other aspects of Ab function, such as Ag opsonization. Our findings emulate those for pDC-reactive opsonophagocytic Ab responses against coxsackie, picorna, and influenza viruses and demonstrate a previously undefined immune correlate of HIV-1 control that may be relevant to HIV vaccine development.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25911748      PMCID: PMC4492937          DOI: 10.4049/jimmunol.1402918

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2.

Authors:  Jane Yang; Andrew M Goetze; Gregory C Flynn
Journal:  Mol Immunol       Date:  2013-12-08       Impact factor: 4.407

2.  Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers.

Authors:  Costin Tomescu; Fuh-Mei Duh; Rebecca Hoh; Anne Viviani; Kara Harvill; Maureen P Martin; Mary Carrington; Steven G Deeks; Luis J Montaner
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

3.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Authors:  Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

4.  Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations.

Authors:  Malgorzata G Mikolajczyk; Nelydia F Concepcion; Theresa Wang; Douglas Frazier; Basil Golding; Carl E Frasch; Dorothy E Scott
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

5.  Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.

Authors:  N Alatrakchi; C Duvivier; D Costagliola; A Samri; A G Marcelin; G Kamkamidze; M Astriti; R Agher; V Calvez; B Autran; C Katlama
Journal:  AIDS       Date:  2005-01-03       Impact factor: 4.177

6.  Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcgammaRIIa genotype.

Authors:  Martyn A French; Sara Tanaskovic; Matthew G Law; Andrew Lim; Sonia Fernandez; Larry D Ward; Anthony D Kelleher; Sean Emery
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

7.  HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.

Authors:  Brinda Emu; Elizabeth Sinclair; Hiroyu Hatano; April Ferre; Barbara Shacklett; Jeffrey N Martin; J M McCune; Steven G Deeks
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

8.  Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers.

Authors:  Martyn A French; Rob J Center; Kim M Wilson; Ibrahim Fleyfel; Sonia Fernandez; Anna Schorcht; Ivan Stratov; Marit Kramski; Stephen J Kent; Anthony D Kelleher
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

9.  Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Authors:  Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

10.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

View more
  12 in total

1.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

2.  Frequencies of Circulating Th1-Biased T Follicular Helper Cells in Acute HIV-1 Infection Correlate with the Development of HIV-Specific Antibody Responses and Lower Set Point Viral Load.

Authors:  Omolara Baiyegunhi; Bongiwe Ndlovu; Funsho Ogunshola; Nasreen Ismail; Bruce D Walker; Thumbi Ndung'u; Zaza M Ndhlovu
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

3.  Association of HIV-1 Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57: 01 Is Only Observed in Viremic Controllers.

Authors:  M Christian Tjiam; Mazmah A Morshidi; Lucy Sariputra; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Acquir Immune Defic Syndr       Date:  2017-11-01       Impact factor: 3.731

4.  Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques.

Authors:  Hongzhao Li; Yan Hai; So-Yon Lim; Nikki Toledo; Jose Crecente-Campo; Dane Schalk; Lin Li; Robert W Omange; Tamara G Dacoba; Lewis R Liu; Mohammad Abul Kashem; Yanmin Wan; Binhua Liang; Qingsheng Li; Eva Rakasz; Nancy Schultz-Darken; Maria J Alonso; Francis A Plummer; James B Whitney; Ma Luo
Journal:  PLoS One       Date:  2018-08-28       Impact factor: 3.240

Review 5.  Association of Diverse Genotypes and Phenotypes of Immune Cells and Immunoglobulins With the Course of HIV-1 Infection.

Authors:  Liuzhe Li; Yan Liu; Miroslaw K Gorny
Journal:  Front Immunol       Date:  2018-11-26       Impact factor: 7.561

Review 6.  Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.

Authors:  Martyn A French; M Christian Tjiam; Laila N Abudulai; Sonia Fernandez
Journal:  Front Immunol       Date:  2017-07-04       Impact factor: 7.561

7.  High-resolution definition of humoral immune response correlates of effective immunity against HIV.

Authors:  Galit Alter; Karen G Dowell; Eric P Brown; Todd J Suscovich; Anastassia Mikhailova; Alison E Mahan; Bruce D Walker; Falk Nimmerjahn; Chris Bailey-Kellogg; Margaret E Ackerman
Journal:  Mol Syst Biol       Date:  2018-03-26       Impact factor: 11.429

8.  HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.

Authors:  Simone I Richardson; Amy W Chung; Harini Natarajan; Batsirai Mabvakure; Nonhlanhla N Mkhize; Nigel Garrett; Salim Abdool Karim; Penny L Moore; Margaret E Ackerman; Galit Alter; Lynn Morris
Journal:  PLoS Pathog       Date:  2018-04-09       Impact factor: 6.823

9.  A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies.

Authors:  Donglai Liu; Chu Wang; Bhavna Hora; Tao Zuo; Nilu Goonetilleke; Michael K P Liu; Mark Berrong; Guido Ferrari; Andrew J McMichael; Tanmoy Bhattacharya; Alan S Perelson; Feng Gao
Journal:  Retrovirology       Date:  2017-10-10       Impact factor: 4.602

10.  Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women.

Authors:  Kimone Leigh Fisher; Jennifer M Mabuka; Aida Sivro; Sinaye Ngcapu; Jo-Ann Shelley Passmore; Farzana Osman; Bongiwe Ndlovu; Quarraisha Abdool Karim; Salim S Abdool Karim; Amy W Chung; Cheryl Baxter; Derseree Archary
Journal:  Front Immunol       Date:  2020-07-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.